What Are Immunoglobulins Key Roles Functions And Clinical Significance

Published

Table of Contents

Immunoglobulins, the cornerstone of adaptive immunity, serve as the body’s precision weapons against pathogens, orchestrating defense through antigen recognition and targeted neutralization. These Y-shaped glycoproteins, produced by plasma cells, exhibit remarkable diversity in structure and function, enabling tailored responses to an ever-evolving array of threats—from viral invaders to autoimmune assaults. Their classification into five distinct isotypes (IgG, IgM, IgA, IgD, IgE) reflects a sophisticated immunological toolkit, each specialized for unique physiological roles, from mucosal protection to allergic mediation. Understanding their mechanisms not only illuminates fundamental immunology but also unlocks therapeutic avenues for disorders ranging from immunodeficiency to chronic inflammation.

Their biological significance extends beyond pathogen clearance, influencing immune regulation, inflammation, and even disease pathogenesis. For instance, IgG’s dominance in serum underscores its critical role in long-term immunity, while IgE’s hyperactivation drives allergic hypersensitivity—a duality that underscores the delicate balance between protection and pathology. Advances in monoclonal antibody therapies have further cemented immunoglobulins’ clinical relevance, transforming treatments for autoimmune diseases, cancer, and infectious disorders. This exploration delves into their molecular architecture, functional diversity, regulatory pathways, and translational applications, revealing how these proteins bridge innate and adaptive immunity to safeguard health.

what are immunoglobulins

Definition and Basic Structure of Immunoglobulins

Immunoglobulins (Ig), commonly known as antibodies, are Y-shaped glycoproteins produced by plasma cells as part of the adaptive immune response. Their primary role is to recognize and neutralize pathogens such as bacteria, viruses, and toxins by binding to specific antigens with high affinity. The structural diversity of immunoglobulins enables them to mediate various immune functions, including neutralization, opsonization, complement activation, and regulation of immune responses.

The fundamental architecture of immunoglobulins is modular, consisting of four polypeptide chains: two identical heavy chains and two identical light chains, linked by disulfide bonds. Each chain comprises variable (V) regions at the amino-terminal ends and constant (C) regions at the carboxyl-terminal ends. The variable regions form the antigen-binding fragment (Fab), which confers specificity to the antibody, while the constant regions determine the effector functions through interactions with immune cells and complement proteins. The hinge region, located between the Fab and the fragment crystallizable (Fc) region, provides flexibility to the molecule, facilitating antigen binding and immune complex formation.

Polypeptide Composition and Functional Domains

The light chains (approximately 25 kDa) are classified into two types: kappa (κ) and lambda (λ), each containing a variable (V) domain and a constant (C) domain. The heavy chains (approximately 50–70 kDa) determine the immunoglobulin class (IgG, IgM, IgA, IgD, IgE) and include a variable domain followed by three or four constant domains (C₁–C₄). The variable regions of both heavy and light chains contribute to the complementarity-determining regions (CDRs), which form the antigen-binding site, while the framework regions (FRs) provide structural stability.

The Fc region is critical for interactions with Fc receptors (FcRs) on immune cells (e.g., macrophages, neutrophils, natural killer cells) and the complement system. These interactions dictate the antibody’s ability to trigger effector functions such as phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), or inflammation. The hinge region, rich in proline residues, allows rotational movement between the Fab and Fc fragments, optimizing antigen accessibility and immune complex formation.

Five Main Classes of Immunoglobulins and Their Characteristics

Immunoglobulins are categorized into five classes based on structural differences in their heavy chains, serum concentrations, and biological roles. Below is a comparative table summarizing their primary locations, functions, and serum half-lives:
Class Primary Location Function Serum Half-Life (days)
IgG Blood serum, extracellular fluid, placenta (IgG1, IgG3) Neutralization of toxins/viruses, opsonization, complement activation, transplacental transfer (IgG1, IgG3), regulation of immune responses (IgG2, IgG4) 21 (IgG1, IgG2, IgG4); 7 (IgG3)
IgM Blood serum, lymphatic system (pentameric form) First antibody produced in primary immune response, potent agglutination, complement activation (C1q binding), B-cell receptor signaling 5–10
IgA Mucosal surfaces (dimeric form in secretions), saliva, breast milk, respiratory/gastrointestinal tracts Mucosal immunity, neutralization of pathogens, prevention of microbial adhesion, secretory IgA (sIgA) protects epithelial surfaces 6 (monomeric); 5 (dimeric)
IgD B-cell surface (monomeric) Antigen receptor on naive B cells, co-stimulation for B-cell activation, regulation of immune tolerance 3
IgE Mucosal surfaces, bound to Fcε receptors on mast cells/basophils Allergic responses, defense against parasites (via eosinophil activation), type I hypersensitivity reactions 2–5
IgG1 is the most clinically significant subclass of IgG, constituting approximately 60–70% of total serum IgG. It is the primary mediator of neutralizing antibodies against viruses (e.g., SARS-CoV-2, influenza) and bacteria (e.g., Streptococcus pneumoniae), as well as the only subclass capable of transplacental transfer, providing passive immunity to newborns. Its high affinity for Fcγ receptors (e.g., FcγRIIIa on NK cells) enables robust ADCC and complement-mediated lysis (via C1q binding). IgG1 is also the most abundant antibody in secondary immune responses, reflecting its role in long-term immunity.

Structural Diversity and Antibody Function

The variable regions of immunoglobulins undergo somatic hypermutation and class switching during an immune response, generating antibodies with enhanced affinity and tailored effector functions. Affinity maturation, driven by T-cell-dependent interactions, refines the antigen-binding site, while isotype switching (via activation-induced cytidine deaminase, AID) replaces the IgM/IgD heavy chain constant regions with those of IgG, IgA, or IgE, optimizing the antibody’s role in different compartments (e.g., blood vs. mucosa).

The quaternary structure of immunoglobulins further diversifies their functions:

  • IgM exists as a pentamer with a J (joining) chain, enabling high avidity and efficient complement activation.
  • IgA forms dimers in secretions, stabilized by a secretory component, which protects it from proteolytic degradation in mucosal environments.
  • IgE binds with high affinity to FcεRI receptors on mast cells, triggering degranulation and immediate hypersensitivity reactions.

    • These structural adaptations ensure immunoglobulins can perform specialized roles in humoral immunity, from pathogen neutralization to immune modulation.

    Mechanisms of Immunoglobulin Function

    Immunoglobulins (Igs) mediate immune responses through precise antigen recognition, pathogen neutralization, and modulation of effector functions. Their functional diversity arises from structural adaptations, including variable regions that bind antigens with high specificity and constant regions that engage immune effector mechanisms. This section explores the molecular interactions governing antigen recognition, pathogen neutralization strategies, and the signaling cascades triggered by Fc receptor binding, emphasizing their roles in adaptive immunity.

    Antigen Recognition via Variable Regions and Complementarity-Determining Regions (CDRs)

    The specificity of immunoglobulins for antigens is conferred by the variable (V) regions of their heavy (V~H~) and light (V~L~) chains, which form the Fab (fragment antigen-binding) region. Within these regions, three hypervariable loops—known as complementarity-determining regions (CDRs)—directly interact with antigenic epitopes. The remaining framework regions (FRs) provide structural stability to the CDRs, ensuring precise antigen binding.

    The three-dimensional structure of the V region resembles a shallow, cleft-like binding site, where CDRs 1 and 2 (located in the V~L~ chain) and CDR3 (spanning both V~H~ and V~L~) contribute most significantly to antigen specificity. For example:

  • CDR3 often dominates binding due to its high sequence variability, generated during V(D)J recombination and somatic hypermutation.
  • CDR1 and CDR2 interact primarily with framework residues, stabilizing the antigen-binding pocket.
    • Key Structural Insight:
    The paratope (antigen-binding site) of an immunoglobulin is shaped by the collective contributions of all six CDRs, with CDR3 frequently determining fine specificity. This diversity allows the immune system to recognize an estimated 10^7–10^11 unique epitopes.

    Pathogen Neutralization Mechanisms

    Immunoglobulins employ multiple strategies to neutralize pathogens, including blocking viral/bacterial attachment, opsonization for phagocytosis, and complement activation. These mechanisms rely on the bivalent or multivalent nature of antibodies, enabling cross-linking and functional synergy.

    Step-by-Step Neutralization Process:
    1. Antigen Binding and Blockade

  • IgG, IgA, and IgM bind to surface proteins (e.g., viral hemagglutinin, bacterial adhesins) via Fab regions, physically preventing pathogen-host cell interactions.
  • Example: IgA dimers in mucosal secretions block rotavirus attachment to intestinal epithelial cells, while IgG1 neutralizes HIV-1 by targeting the gp120 envelope glycoprotein.

    • 2. Opsonization and Phagocytosis

  • Pathogen-bound antibodies (e.g., IgG1/3) are recognized by Fcγ receptors (FcγRs) on phagocytes (macrophages, neutrophils), tagging pathogens for receptor-mediated endocytosis.
  • Mechanism: FcγR engagement triggers actin cytoskeleton rearrangement, forming phagosomes that fuse with lysosomes for degradation.

    • 3. Complement System Activation

  • IgM and IgG (especially subclasses IgG1/3) activate the classical complement pathway via C1q binding to Fc regions, leading to:
  • Opsonization (C3b deposition).
  • Membrane Attack Complex (MAC) formation (C5b–C9), lysing enveloped viruses/bacteria.
  • Example: IgM-mediated complement activation neutralizes Streptococcus pneumoniae by generating C3b and C5a, enhancing phagocytosis and inflammation.
    • Clinical Relevance:
    Deficiencies in IgG subclasses (e.g., IgG2) impair opsonization of encapsulated bacteria (e.g., Haemophilus influenzae), increasing susceptibility to recurrent infections.

    Fc Receptor-Mediated Signaling Pathways and Immunological Effects

    The Fc region of immunoglobulins interacts with Fc receptors (FcRs) on immune cells, initiating distinct signaling cascades that regulate inflammation, phagocytosis, and antibody-dependent cellular cytotoxicity (ADCC). Below is a flowchart-style breakdown of key pathways:
    Fc ReceptorCell TypeDownstream Signaling PathwayImmunological Outcome
    FcγRI (CD64)Monocytes, MacrophagesSYK/PI3K/AKT → NF-κB activationPhagocytosis, cytokine production (TNF-α, IL-12)
    FcγRIIa (CD32a)Neutrophils, B CellsITAM-mediated SYK/LYN → ERK/MAPK, PLCγ2ADCC, antibody-dependent phagocytosis (ADP)
    FcγRIIIa (CD16a)NK Cells, MacrophagesSYK/ZAP-70 → Granzyme/B perforin releaseADCC (e.g., against tumor cells or virus-infected targets)
    FcεRIMast Cells, BasophilsSYK/LAT → Calcium influx, degranulation (histamine, leukotrienes)Allergic responses (Type I hypersensitivity)
    FcαRI (CD89)Neutrophils, MonocytesSYK/PI3K → ROS production, phagocytosisEnhanced clearance of IgA-coated pathogens (e.g., Neisseria meningitidis)
    Key Pathway Details:
  • ITAM (Immunoreceptor Tyrosine-Based Activation Motif) Phosphorylation:
    • FcγRs (e.g., FcγRIIa) lack intrinsic kinase activity but recruit SYK via ITAMs, leading to:
  • Phospholipase Cγ (PLCγ) activation → IP₃-mediated Ca²⁺ release → NFAT transcription factor activation.
  • PI3K/AKT pathway → Cell survival and cytoskeletal rearrangements.

    • - Inhibitory FcγRs (e.g., FcγRIIb):
    Contain ITIM (Immunoreceptor Tyrosine-Based Inhibition Motif), recruiting SHIP/SHP-1 to dampen immune responses and prevent autoimmunity.

    Therapeutic Targeting:
    Monoclonal antibodies (e.g., trastuzumab for HER2⁺ breast cancer) exploit FcγRIIIa (CD16a) on NK cells to induce ADCC, demonstrating the clinical utility of Fc-mediated effector functions.

    what are immunoglobulins - Ilustrasi 2

    Production and Regulation of Immunoglobulins

    Immunoglobulin (Ig) production is a tightly regulated process governed by B-cell development, antigen exposure, and molecular signals that dictate class switching and affinity refinement. The progression from naive B cells to antibody-secreting plasma cells involves distinct stages, each marked by genetic rearrangements, receptor editing, and selective pressures that shape the adaptive immune response. Molecular mediators such as cytokines and transcription factors orchestrate immunoglobulin class switching, ensuring appropriate antibody isotypes are produced in response to pathogens or environmental cues.

    The development of B cells from hematopoietic stem cells to mature, antibody-secreting plasma cells is a multi-stage process characterized by sequential checkpoint controls. Each stage influences the diversity, specificity, and functional capacity of immunoglobulins, with critical implications for adaptive immunity. Below, the stages of B-cell maturation are detailed alongside their roles in class switching and affinity maturation, followed by an analysis of the molecular signals that regulate these processes.

    Stages of B-Cell Development and Their Role in Immunoglobulin Maturation

    B-cell development occurs primarily in the bone marrow and is divided into sequential stages: pro-B cell, pre-B cell, immature B cell, naive B cell, and plasma cell. Each stage is defined by distinct genetic rearrangements, receptor expression, and selection mechanisms that contribute to immunoglobulin diversity and functionality.
    Key Checkpoints in B-Cell Development:
  • Pro-B cell: Heavy chain (IgH) D-J rearrangement and allelic exclusion.
  • Pre-B cell: V-DJ rearrangement and pre-B cell receptor (pre-BCR) expression.
  • Immature B cell: Light chain (IgL) V-J rearrangement and surface IgM expression.
  • Naive B cell: Positive and negative selection in the periphery.
  • Plasma cell: Terminal differentiation with high-rate Ig secretion.
    • Pro-B to Pre-B Cell Transition:
    During the pro-B cell stage, the heavy chain locus undergoes D-J rearrangement, followed by V-DJ recombination, resulting in a functional μ (IgM) heavy chain. Successful rearrangement triggers allelic exclusion, ensuring monoclonality. The pre-BCR, composed of the μ chain, surrogate light chains (VpreB and λ5), and Igα/Igβ signaling subunits, is expressed on the cell surface. This receptor mediates proliferation and receptor editing, allowing cells with non-functional or autoreactive BCRs to undergo further rearrangements.

    Pre-B to Immature B Cell Transition:
    In the pre-B cell stage, cells undergo light chain (κ or λ) V-J rearrangement. Successful light chain expression leads to the formation of a complete IgM BCR on the surface of immature B cells. These cells then migrate to the periphery, where they undergo negative selection to eliminate self-reactive clones. Survivors become naive B cells, capable of responding to foreign antigens.

    Naive B Cell Activation and Plasma Cell Differentiation:
    Upon encountering antigen in secondary lymphoid tissues, naive B cells undergo activation-induced cytidine deaminase (AID)-mediated somatic hypermutation (SHM) and class switch recombination (CSR) in germinal centers. Affinity maturation occurs through iterative cycles of mutation and selection, favoring high-affinity BCRs. Activated B cells differentiate into plasma cells (short-lived or long-lived) or memory B cells, with plasma cells specializing in high-rate Ig secretion.

    Molecular Regulation of Immunoglobulin Class Switching

    Class switch recombination (CSR) enables B cells to replace the constant region of the μ/δ heavy chain with downstream isotypes (IgG, IgA, IgE), tailoring the immune response to the pathogen type. This process is regulated by cytokine signals, transcription factors, and AID-mediated DNA cleavage at switch (S) regions upstream of target isotypes.
    Mechanism of CSR:
    1. AID (Activation-Induced Cytidine Deaminase) introduces mutations in S regions, forming single-strand breaks.
    2. Uracil DNA glycosylase (UNG) and APE1 process breaks into double-strand DNA gaps.
    3. Non-homologous end joining (NHEJ) ligates distant S regions, deleting intervening DNA.
    4. Transcription factors (e.g., STAT6, IRF4) and cytokines direct isotype-specific switching.
    Cytokine-Dependent Class Switching:
    The choice of Ig isotype is dictated by T-cell-derived cytokines and intrinsic B-cell signals, with distinct patterns observed in different immune contexts:

    - IgG1 and IgG3: Driven by IFN-γ (via STAT1) and IL-21 (via STAT3), promoting Th1 responses.

  • IgG2a (mouse) / IgG2 (human): Induced by IFN-γ and IL-12, enhancing opsonization.
  • IgG4 (human): Regulated by IL-4 and IL-13 (via STAT6), associated with immune regulation.
  • IgA: Stimulated by TGF-β (via SMAD3/4) and BAFF, critical for mucosal immunity.
  • IgE: Induced by IL-4 and IL-13, promoting type I hypersensitivity and anti-parasitic responses.

    • Transcription Factors in CSR:
    Key transcription factors include:

  • STAT6 (IgE, IgG4): Activated by IL-4/IL-13 signaling.
  • IRF4 (IgG1, IgA): Required for germinal center reactions.
  • SMAD3/4 (IgA): Mediates TGF-β signaling.
  • PU.1 and BLIMP-1: Regulate plasma cell differentiation and Ig secretion.

    • Example: TGF-β-Mediated IgA Switching
    In mucosal tissues, TGF-β binds its receptor (TGFBR2), activating SMAD2/3, which translocates to the nucleus. SMAD complexes cooperate with AP-1 and IRF4 to enhance transcription of activation-induced cytidine deaminase (AID) and IgA-specific switch regions, facilitating CSR to IgA.

    Comparison of Primary and Secondary Immune Responses

    The adaptive immune system distinguishes between primary (first exposure) and secondary (subsequent exposures) responses, with key differences in immunoglobulin class, affinity, and memory cell formation. Below is a comparative table summarizing these features:
    Response Type Dominant Ig Class Affinity Maturation Memory Cell Formation
    Primary Response IgM (initial), followed by low-affinity IgG/IgA Limited; low somatic hypermutation (SHM) in germinal centers Absent or minimal; few long-lived plasma cells or memory B cells
    Secondary Response IgG (predominant), with subclass variation (IgG1, IgG3); IgA in mucosal sites High; extensive SHM and selection for high-affinity BCRs in germinal centers Abundant; long-lived plasma cells and memory B cells ensure rapid, robust recall
    Key Observations:
  • Primary responses are characterized by IgM dominance and a lag phase (~5–10 days) before detectable antibodies appear. Affinity maturation is minimal due to limited germinal center activity.
  • Secondary responses exhibit isotype switching to IgG/IgA, higher titers, and rapid kinetics (2–3 days) due to pre-existing memory B cells. Affinity maturation is pronounced, yielding antibodies with 100–1000-fold higher affinity than primary responses.
  • Memory B cells persist for decades, enabling lifelong immunity (e.g., measles, tetanus). Long-lived plasma cells in bone marrow maintain low-level antibody production.

    • Clinical Relevance:
    The distinction between primary and secondary responses underpins vaccination strategies. For example, the BCG vaccine induces a primary response with IgM followed by IgG, while booster doses exploit memory B cells to enhance IgG titers and affinity, ensuring prolonged protection.

    Clinical Applications and Immunoglobulin Therapies

    Immunoglobulin-based therapies represent a cornerstone of modern immunology and clinical medicine, offering targeted interventions for autoimmune disorders, immunodeficiency syndromes, and infectious diseases. Passive immunization leverages preformed antibodies to confer immediate, albeit transient, protection, while active immunization stimulates the host’s endogenous immune system to generate long-lasting adaptive responses. Intravenous immunoglobulin (IVIG) stands as a versatile therapeutic modality, capable of modulating immune dysregulation through mechanisms beyond simple antibody replacement, including neutralization of pathogenic autoantibodies, modulation of complement activity, and inhibition of pro-inflammatory cytokines.

    The clinical utility of immunoglobulins extends to monoclonal antibody therapies, which exploit precision-engineered antibodies to disrupt specific molecular pathways implicated in disease pathogenesis. These therapies have revolutionized the management of conditions ranging from hematologic malignancies to chronic inflammatory disorders, often achieving outcomes previously unattainable with conventional treatments.

    Comparison of Passive and Active Immunization Strategies

    Passive immunization involves the administration of exogenous antibodies, either derived from pooled human plasma (e.g., IVIG) or recombinant sources, to provide immediate protection or mitigate disease activity. This approach is particularly valuable in scenarios requiring rapid immune intervention, such as post-exposure prophylaxis for tetanus or rabies, or the treatment of primary immunodeficiencies where the host lacks functional antibody production. The effects of passive immunization are temporary, typically lasting weeks to months, as the administered antibodies are gradually catabolized.

    In contrast, active immunization relies on the administration of antigens—either live attenuated pathogens, inactivated vaccines, or recombinant proteins—to stimulate the host’s immune system. This process triggers the production of memory B and T cells, as well as long-lasting antibody titers, offering durable protection against reinfection. Vaccination campaigns have eradicated or significantly reduced the global burden of diseases such as smallpox, polio, and measles, underscoring the transformative impact of active immunization. However, active immunization requires time to confer immunity, rendering it unsuitable for acute or post-exposure scenarios.

    Key distinctions between passive and active immunization:

  • Onset of action: Passive immunization provides immediate protection, while active immunization requires days to weeks for efficacy.
  • Duration of protection: Passive effects are transient (weeks to months), whereas active immunity can persist for years or decades.
  • Host dependency: Passive immunity is independent of the recipient’s immune competence, making it critical for immunocompromised individuals, whereas active immunization depends on a functional immune system.
  • Adverse events: Passive therapies may carry risks of infusion reactions or transmission of blood-borne pathogens, while active immunization can induce local or systemic reactions (e.g., fever, anaphylaxis) and, rarely, vaccine-associated adverse events.

    • Intravenous Immunoglobulin (IVIG) in Autoimmune and Immunodeficiency Disorders

    IVIG is a plasma-derived therapeutic composed of highly purified polyclonal antibodies derived from thousands of donors. Its clinical applications span immunodeficiency syndromes, autoimmune diseases, and inflammatory conditions, where it exerts immunomodulatory effects through multiple mechanisms, including:
  • Neutralization of pathogenic autoantibodies (e.g., in myasthenia gravis or autoimmune hemolytic anemia).
  • Modulation of complement activity via inhibition of the classical pathway, reducing antibody-mediated tissue damage.
  • Downregulation of pro-inflammatory cytokines (e.g., TNF-α, IL-6) and upregulation of anti-inflammatory mediators (e.g., IL-10).
  • Saturation of Fc receptors on immune cells, preventing antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis of self-antigens.

    • Primary indications for IVIG therapy:

  • Primary immunodeficiencies: Chronic granulomatous disease, common variable immunodeficiency (CVID), and X-linked agammaglobulinemia, where IVIG replaces deficient antibodies and reduces infections.
  • Autoimmune diseases: Idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, and Guillain-Barré syndrome, where IVIG suppresses autoantibody-mediated destruction of platelets or peripheral nerves.
  • Neurological disorders: Multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy (CIDP), where IVIG stabilizes disease progression.
  • Hematologic conditions: Autoimmune hemolytic anemia and paroxysmal nocturnal hemoglobinuria (PNH), where IVIG mitigates complement-mediated hemolysis.

    • Mechanisms of IVIG in autoimmune diseases:

    IVIG’s efficacy in autoimmune disorders is attributed not only to its antibody content but also to its influence on immune cell function. For instance, IVIG can:
    1. Block Fcγ receptors on macrophages and neutrophils, reducing ADCC and phagocytosis of autoantibody-coated cells.
    2. Induce regulatory T cells (Tregs) and suppress Th17 responses, shifting the immune milieu toward tolerance.
    3. Inhibit apoptosis of autoreactive B cells, potentially limiting autoantibody production.
    4. Modulate dendritic cell maturation, reducing antigen presentation and T-cell activation.
    Challenges and considerations:
  • Dosage variability: Standard regimens range from 0.4 to 2 g/kg per infusion, with high-dose IVIG (1–2 g/kg) often required for autoimmune indications.
  • Adverse effects: Headache, fever, chills, and aseptic meningitis are common; rare but severe complications include thromboembolic events and acute renal failure (particularly with sucrose-stabilized formulations).
  • Cost and accessibility: IVIG remains expensive, limiting its use in resource-constrained settings despite its life-saving potential.

    • Monoclonal Antibody Therapies in Immunology and Oncology

    Monoclonal antibodies (mAbs) represent a class of biologics engineered to target specific antigens with high affinity and specificity. Unlike polyclonal IVIG, mAbs are produced through recombinant DNA technology, enabling precise modulation of immune pathways. Their clinical applications are diverse, encompassing oncology, rheumatology, and infectious disease management. Below is a curated table of select monoclonal antibody therapies, categorized by target and therapeutic indication.

    Table: Key Monoclonal Antibody Therapies

    Therapy Target Indication Mechanism
    Rituximab CD20 (expressed on B cells) Rheumatoid arthritis, systemic lupus erythematosus (SLE), non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) Depletes B cells via ADCC, complement-dependent cytotoxicity (CDC), and apoptosis induction; reduces autoantibody production.
    Infliximab TNF-α Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis Neutralizes soluble and transmembrane TNF-α, inhibiting pro-inflammatory signaling and reducing tissue damage.
    Adalimumab TNF-α Same as infliximab; also approved for juvenile idiopathic arthritis (JIA) and hidradenitis suppurativa Fully human IgG1 mAb with prolonged half-life (~2 weeks), enabling subcutaneous administration.
    Omalizumab IgE (binds FcεRI) Severe allergic asthma, chronic idiopathic urticaria Reduces free IgE levels, preventing mast cell and basophil activation; downregulates FcεRI expression.
    Trastuzumab HER2/neu (tyrosine kinase receptor) HER2-positive breast cancer, gastric/gastroesophageal junction adenocarcinoma Inhibits HER2 signaling, induces ADCC, and enhances chemotherapy efficacy via antibody-drug conjugate (ADC) mechanisms.
    Bevacizumab Vascular endothelial growth factor (VEGF) Metastatic colorectal cancer, non-small cell lung cancer (NSCLC), glioblastoma Blocks VEGF-mediated angiogenesis, starving tumors of nutrient supply and reducing metastasis.
    Secukinumab IL-17A Psoriasis, psoriatic arthritis, ankylosing spondylitis Inhibits IL-17A, a pro-inflammatory cytokine critical for neutrophil recruitment and keratinocyte hyperproliferation.
    Nivolumab PD-1 (programmed cell death protein 1) Melanoma, NSCLC, renal cell carcinoma, Hodgkin lymphoma Blocks PD-1/PD-L1 interaction, restoring T-cell-mediated antitumor

    what are immunoglobulins - Ilustrasi 3

    Immunoglobulin Dysfunction and Associated Disorders

    Immunoglobulin dysfunction encompasses a spectrum of conditions characterized by quantitative or qualitative defects in antibody production, leading to heightened susceptibility to infections, autoimmune phenomena, or both. These disorders may arise from genetic mutations, acquired factors, or dysregulated immune responses, with clinical manifestations varying based on the underlying mechanism. Primary immunodeficiencies (PIDs) linked to immunoglobulin deficiencies often present early in life, whereas secondary immunodeficiencies emerge later due to extrinsic stressors such as infections, therapies, or systemic diseases. Autoimmune disorders further complicate this landscape by involving autoantibody-mediated tissue damage, underscoring the dual role of immunoglobulins in both defense and pathology.

    The classification of immunoglobulin dysfunctions requires a systematic approach, distinguishing between congenital and acquired etiologies while correlating laboratory findings with clinical phenotypes. Diagnostic criteria for primary immunodeficiencies rely on standardized thresholds for serum immunoglobulin levels, response to vaccinations, and genetic testing, whereas secondary deficiencies are inferred from patient history and reversible risk factors. Below, the focus shifts to the pathogenesis, diagnostic frameworks, and clinical distinctions of these disorders, including their autoimmune manifestations.

    Primary Immunodeficiency Diseases Linked to Immunoglobulin Deficiencies

    Primary immunodeficiencies (PIDs) involving immunoglobulin deficiencies are typically inherited disorders that disrupt B-cell development, differentiation, or antibody production. These conditions often present with recurrent sinopulmonary infections, failure to respond to vaccinations, and elevated susceptibility to encapsulated bacteria. Diagnostic criteria for immunoglobulin-related PIDs are outlined by expert consensus panels, including the International Union of Immunological Societies (IUIS), and typically involve:

    - Serum immunoglobulin levels below the 2nd percentile for age (e.g., IgG < 400 mg/dL in adults, IgA < 7 mg/dL in children).

  • Reduced vaccine-specific antibody responses (e.g., post-Haemophilus influenzae type b or pneumococcal vaccination titers).
  • Genetic confirmation via targeted sequencing (e.g., BTK mutations in X-linked agammaglobulinemia, ICOS or TACI variants in Common Variable Immunodeficiency).

    • The following disorders represent key examples of immunoglobulin-related PIDs, each with distinct genetic and clinical profiles:

    X-Linked Agammaglobulinemia (XLA)

    Caused by mutations in the BTK gene, XLA results in a near-complete absence of mature B cells (B-cell lymphopenia) and profoundly low serum immunoglobulins. Patients typically present in infancy or early childhood with recurrent bacterial infections (e.g., Streptococcus pneumoniae, Haemophilus influenzae), arthritis, and enteroviral infections. Diagnostic criteria include:
  • Absent or severely reduced B cells (< 2% of lymphocytes).
  • Undetectable IgG, IgA, and IgM (< 1% of normal levels).
  • Normal T-cell counts and NK-cell function.

    • Common Variable Immunodeficiency (CVID)

    The most prevalent symptomatic primary immunodeficiency, CVID is characterized by hypogammaglobulinemia with reduced serum IgG, IgA, and/or IgM, but normal B-cell counts. Etiology is heterogeneous, involving defects in B-cell differentiation, T-cell help, or cytokine signaling (e.g., ICOS, TACI, BAFF-R mutations). Clinical features include:
  • Recurrent respiratory tract infections (e.g., bronchiectasis, pneumonia).
  • Autoimmune manifestations (e.g., autoimmune hemolytic anemia, thrombocytopenia) in 20–30% of cases.
  • Granulomatous inflammation (e.g., lymphadenopathy, splenomegaly).
  • Increased malignancy risk (e.g., lymphoma, gastric cancer).

    • Selective IgA Deficiency (IgAD)

    The most common PID, IgAD is defined by serum IgA levels < 7 mg/dL with normal IgG and IgM. While often asymptomatic, complications include:
  • Recurrent sinopulmonary or gastrointestinal infections.
  • Atopic diseases (e.g., asthma, allergic rhinitis).
  • Autoimmune disorders (e.g., celiac disease, rheumatoid arthritis).
  • Anaphylactic reactions to blood products due to anti-IgA antibodies.

    • Hyper-IgM Syndromes (HIGM)

    A group of disorders characterized by elevated IgM with low IgG, IgA, and/or IgE, caused by defects in class-switch recombination (e.g., CD40L, AID, UNG mutations). Clinical features include:
  • Severe pyogenic infections (e.g., Pneumocystis jirovecii, Cryptosporidium).
  • Opportunistic infections (e.g., Pneumocystis, CMV).
  • Granulomatous colitis and autoimmune lymphoproliferative syndrome (ALPS)-like features.

    • Secondary Immunodeficiencies Caused by Extrinsic Factors

    Secondary immunodeficiencies arise from acquired conditions that impair immunoglobulin production or function, often reversibly. These include malnutrition, immunosuppressive therapies, chronic infections, and malignancies. Unlike PIDs, secondary deficiencies lack genetic underpinnings and may resolve with targeted interventions. Below is a comparative table highlighting key etiologies, affected immunoglobulin classes, and clinical presentations:
    Type Cause Ig Class Affected Key Symptoms
    Nutritional Immunodeficiency Protein-energy malnutrition (e.g., kwashiorkor), zinc/copper deficiency, vitamin A/E deficiency Pan-hypogammaglobulinemia (IgG, IgA, IgM reduction); impaired vaccine responses
    • Recurrent bacterial infections (e.g., Staphylococcus aureus, Salmonella)
    • Delayed wound healing and diarrhea
    • Increased mortality from respiratory infections in children
    Immunosuppressive Therapy-Induced Chemotherapy (e.g., alkylating agents, rituximab), corticosteroids, calcineurin inhibitors (e.g., tacrolimus) IgG reduction (dose-dependent); IgA/IgM may also decline
    • Increased risk of Pneumocystis jirovecii pneumonia and Aspergillus infections
    • Vaccine hyporesponsiveness (e.g., post-pneumococcal conjugate vaccine)
    • Chronic mucocutaneous candidiasis (with prolonged use)
    HIV-Associated Immunodeficiency CD4+ T-cell depletion (<200 cells/µL) with progressive B-cell dysfunction Pan-hypogammaglobulinemia; impaired memory B-cell differentiation
    • Recurrent Streptococcus pneumoniae, Haemophilus influenzae, and Mycobacterium tuberculosis infections
    • Opportunistic infections (e.g., Cryptococcus neoformans, Toxoplasma gondii)
    • Autoimmune phenomena (e.g., immune thrombocytopenic purpura, rheumatoid arthritis)
    Chronic Kidney Disease (CKD)/Nephrotic Syndrome Proteinuria-induced loss of IgG; impaired B-cell function due to uremia Selective IgG loss (hypogammaglobulinemia); IgA may be elevated paradoxically
    • Frequent bacterial infections (e.g., Staphylococcus, Pseudomonas)
    • Increased susceptibility to hepatitis B and C
    • Autoimmune manifestations (e.g., membranous nephropathy with anti-PLA2R antibodies)
    Multiple Myeloma Plasma cell dyscrasia with monoclonal immunoglobulin production; suppression of polyclonal antibodies Pan-hypogammaglobulinemia (due to "free light chain" excess and immune paralysis)
    • Recurrent bacterial infections (e.g., Streptococcus pneumoniae, Staphylococcus aureus)
      • <

      Immunoglobulins epitomize the adaptive immune system’s elegance and precision, where structural versatility meets functional specialization to combat biological threats with surgical accuracy. From the antigen-binding specificity of their variable regions to the effector functions mediated by Fc receptors, these molecules exemplify nature’s engineering prowess in immune defense. Their clinical applications—spanning passive immunization therapies to monoclonal antibody innovations—demonstrate how immunological insights translate into life-saving interventions. Yet, their dysregulation also underscores the fragility of immune homeostasis, where deficiencies or hyperactivity manifest as devastating disorders. As research continues to unravel their complexities, immunoglobulins remain a testament to the body’s adaptive resilience, offering both diagnostic markers and therapeutic targets in the fight against disease.

      FAQ

      what are immunoglobulins used for?

      Q: What medical or biological purposes do immunoglobulins serve in the human body?

      what are immunoglobulins igg iga igm?

      Q: What are the differences between the main types of immunoglobulins—IgG, IgA, and IgM—and what do they do?

      what are immunoglobulins blood test?

      Q: How does an immunoglobulins blood test work, and what conditions can it help diagnose?

      what are immunoglobulins and their functions?

      Q: What are immunoglobulins, and what specific functions do they perform in immunity?

      what are immunoglobulins a g m?

      Q: What do the letters "A," "G," and "M" stand for in immunoglobulins (IgA, IgG, IgM), and how do they differ?

      what are immunoglobulins made of?

      Q: What are immunoglobulins made of at the molecular level?

      Leave a Comment

      Comments are moderated before appearing. The data you submit is processed according to the Privacy Policy of Voltefac.